Northpond Ventures, LLC Candel Therapeutics, Inc. Transaction History
Northpond Ventures, LLC
- $27.7 Million
- Q3 2024
A detailed history of Northpond Ventures, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Northpond Ventures, LLC holds 1,935,215 shares of CADL stock, worth $10.4 Million. This represents 48.35% of its overall portfolio holdings.
Number of Shares
1,935,215
Previous 1,935,215
-0.0%
Holding current value
$10.4 Million
Previous $12 Million
11.78%
% of portfolio
48.35%
Previous 41.58%
Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
87Shares Held
16.6MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$13.1 Million0.16% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.15MShares$11.6 Million8.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$9.32 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA881KShares$4.73 Million0.41% of portfolio
-
Black Rock Inc. New York, NY823KShares$4.42 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $155M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...